Профиль Critical Outcome Technologies Inc Registered Shs
Подробнее
Cotinga Pharmaceuticals, Inc. is engaged in the development of therapeutics for the treatment of cancer and other unmet medical needs. It offers COTI-2 and COTI-219 pipelines. The COTI-2 pipeline targets gynecologic cancers and head and neck squamous cell carcinoma. The COTI-219 pipeline focuses on the treatment of lung, colorectal, pancreatic and thyroid cancers. The company was founded on October 13, 2006 and is headquartered in Toronto, Canada.